About
allogeneic FcR?-deficient natural killer cells
Areas of Focus
Categories
Stem Cell & Cellular TherapyBiotech
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
162
By Phase
PHASE1: 1PHASE1/PHASE2: 1
By Status
SUSPENDED: 1RECRUITING: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06677710Lead Sponsor
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
PHASE1Suspended
34 participants
Started: Jun 30, 2026 · Completed: Dec 31, 2028
NCT06119685Lead Sponsor
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
PHASE1/PHASE2Recruiting
128 participants
Started: Oct 25, 2023 · Completed: Dec 31, 2029
Locations (1)
Headquarters
San Francisco, CA, United States
Map
Loading map...